Loading
Screening 424 women with ER-negative breast cancer found androgen receptor in 12%; the prostate drug bicalutamide held the disease stable for six months in 19% of them, the first clinical proof that the LAR subtype can be treated through its receptor.
TBCRC 011 tested bicalutamide 150 mg daily in ER/PgR-negative advanced breast cancer with central AR immunohistochemistry (over 10% nuclear staining positive). Of 424 patients screened, 12% were AR-positive. The six-month clinical benefit rate was 19% (95% CI 7 to 39) and median progression-free survival 12 weeks; no grade 4 or 5 treatment-related events occurred.
It fixes the AR-positive share of ER-negative disease at about one in eight and shows anti-androgens give modest, non-toxic benefit, the rationale for enzalutamide and later CDK4/6 and PI3K combinations in LAR tumours.
Shares Androgen receptor signalling, Androgen receptor, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Sara M. Tolaney, Clinical Cancer Research, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Bicalutamide, Androgen receptor, Triple-negative breast cancer (TNBC).
Shares Bicalutamide, Metastatic triple-negative breast cancer.
Shares Sara M. Tolaney, Immunohistochemistry (IHC), Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Bicalutamide, Androgen receptor, Triple-negative breast cancer (TNBC).
Shares Clinical Cancer Research, Androgen receptor, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).